Alcoholic Hepatitis - Severity and Steroids

Key Points

• Alcohol-associated hepatitis is a syndrome of acute jaundice and inflammation, not simply any abnormal liver tests in a person who drinks.
• Exclude infection, biliary obstruction, viral hepatitis, DILI, and ischemic injury before committing to the diagnosis.
• Nutrition and alcohol-use-disorder treatment are core therapies.
• Corticosteroids are reserved for severe disease and require screening for major contraindications.
• Use an early treatment-response score such as Lille to stop ineffective corticosteroid therapy.
• AKI, infection, encephalopathy, GI bleeding, and multi-organ failure markedly worsen prognosis.
• Selected nonresponders should be considered for early transplant evaluation.

Algorithm

1. Confirm recent jaundice and a compatible heavy-alcohol exposure pattern.
2. Exclude infection, biliary obstruction, viral hepatitis, DILI, and ischemic causes.
3. Assess severity with MELD and a validated alcohol-hepatitis severity tool.
4. Start nutrition, thiamine, alcohol-withdrawal management, and treatment of cirrhosis complications.
5. For severe disease, screen carefully for steroid contraindications.
6. Start prednisolone when benefits outweigh risks.
7. Calculate an early response score and discontinue steroids in nonresponders.
8. Engage addiction treatment and consider transplant evaluation when severe disease does not improve.

Clinical Synopsis & Reasoning

Alcohol-associated hepatitis is a clinical syndrome of recent onset or worsening jaundice in a person with sustained heavy alcohol use, typically with bilirubin elevation, AST greater than ALT but usually both below the extreme levels seen with ischemic or acetaminophen injury, and systemic inflammation. Many patients have underlying cirrhosis even if it was not previously diagnosed. Fever, leukocytosis, tender hepatomegaly, ascites, encephalopathy, and renal dysfunction may accompany severe disease.

The diagnosis is usually clinical but should not be assumed merely because alcohol use is present. Exclude biliary obstruction, viral hepatitis, drug-induced liver injury, ischemic hepatitis, autoimmune disease, and sepsis. Infection is particularly important because patients are vulnerable to spontaneous bacterial peritonitis, pneumonia, urinary infection, bacteremia, and skin infection. Diagnostic paracentesis is indicated in hospitalized patients with cirrhosis and ascites unless a clear contraindication exists.

Severity assessment guides treatment. MELD is widely used to estimate short-term risk. Historically the Maddrey discriminant function has been used to identify severe disease, and Lille score after several days of corticosteroid therapy helps determine whether treatment is providing benefit. Kidney injury, infection, gastrointestinal bleeding, shock, and multi-organ failure worsen prognosis and may preclude steroid therapy.

Treatment Strategy & Disposition

Stop alcohol completely and treat alcohol withdrawal safely when present. Provide adequate calories and protein rather than imposing protein restriction because malnutrition is common and worsens outcomes. Give thiamine before carbohydrate in patients at risk for deficiency, replace electrolytes, and manage ascites, encephalopathy, infection, and AKI according to cirrhosis guidance. Early involvement of addiction medicine and social work is part of disease treatment, not an optional discharge add-on.

For severe alcohol-associated hepatitis, prednisolone can improve short-term outcomes in carefully selected patients. Exclude or control major infection before initiation and avoid corticosteroids when there is uncontrolled sepsis, active gastrointestinal bleeding, severe uncontrolled renal failure, or another major contraindication. Reassess treatment response using the Lille score after the recommended interval and stop corticosteroids in clear nonresponders to avoid prolonged infection risk without benefit.

Patients with severe disease, worsening MELD, AKI, encephalopathy, or multi-organ failure should be managed in a center with hepatology expertise. Early liver-transplant evaluation may be appropriate for selected patients with severe disease who fail medical therapy; rigid abstinence-duration rules are increasingly replaced by structured multidisciplinary assessment of relapse risk and psychosocial factors.

Epidemiology / Risk Factors

• Alcohol-associated liver disease is a major cause of liver-related morbidity and mortality.
• Alcohol-associated hepatitis often occurs in patients with underlying fibrosis or cirrhosis.
• Malnutrition is common in hospitalized patients.
• Women can develop severe alcohol-related liver injury at lower cumulative alcohol exposure than men.

Investigations

Contraindications to Steroids

Pharmacology

Prognosis / Complications

• Mild disease may improve substantially with abstinence and nutrition.
• Severe alcohol-associated hepatitis has high short-term mortality, especially with kidney or multi-organ failure.
• Lille nonresponse identifies patients unlikely to benefit from continuing corticosteroids.
• Sustained abstinence is the strongest determinant of long-term survival after the acute episode.

Patient Education / Counseling

• Explain that complete abstinence is essential because continued alcohol exposure can cause recurrent or progressive liver failure.
• Offer evidence-based medication and behavioral treatment for alcohol use disorder when medically appropriate.
• Discuss infection warning signs and the risks of corticosteroid therapy if used.
• Include family or support persons in relapse-prevention planning when the patient agrees.

Notes

The acute hospitalization should not be separated from long-term alcohol treatment. A patient can survive the inflammatory episode and still have a poor prognosis if recurrent drinking continues, while sustained abstinence can transform long-term outcomes.

Corticosteroids are not a reflex for jaundice in a person with alcohol use. They are a time-limited therapy for selected severe disease after infection and major contraindications have been addressed.

References

1. AASLD: Alcohol-Associated Liver Disease Practice Guidance — Link
2. AASLD Practice Guidelines — Link